Insights - Prana Biotech (PRAN) said on Thursday that after further analysis of a failed Alzheimer’s study, the company will likely move forward with lead drug candidate PBT2 in … Continue Reading
Read nowInsights - Tax inversion has been a trend in the biotech and pharmaceutical industry, involvinga U.S.-based company acquiring a smaller foreign company in order to reduce paid … Continue Reading
Read nowInsights - Pozen (POZN) shares dropped on news that the FDA has accepted for review the refiling of a NDA for two aspirin candidates, PA8140 and -32540. … Continue Reading
Read nowInsights - La Jolla Pharmaceutical (LJPC) shares jumped 21% in early trading on Tuesday following news that pipeline candidate LJPC-1010 demonstrated positive activity in a pre-clinical model … Continue Reading
Read nowInsights - Exelixis (EXEL) on Monday announced positive top-line results from a phase 3 trial of the MEK inhibitor cobimetinib in combination with Zelboraf (vemurafenib) in untreated patients with melanoma harboring … Continue Reading
Read nowInsights - The FDA has informed Salix Pharmaceuticals (SLXP) that Relistor (methylnaltrexone bromide) can be approved for the treatment of constipation in patients taking opioids for chronic non-cancer … Continue Reading
Read nowRecap - Great news for longtime PropThink readers on Monday morning – BioDelivery Sciences (BDSI) announced positive results from the second of two phase 3 studies testing BEMA-Buprenorphine in chronic pain … Continue Reading
Read now
